Mustang Bio, Inc.
MBIO
$1.13
-$0.07-5.44%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -58.12% | -56.23% | -55.36% | -57.31% | -33.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -91.90% | -91.88% | -80.89% | -75.25% | -65.03% |
| Operating Income | 91.90% | 91.88% | 80.89% | 75.25% | 65.03% |
| Income Before Tax | 90.03% | 89.78% | 73.28% | 69.47% | 62.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 90.03% | 89.78% | 73.28% | 69.47% | 62.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.03% | 89.78% | 73.28% | 69.47% | 62.61% |
| EBIT | 91.90% | 91.88% | 80.89% | 75.25% | 65.03% |
| EBITDA | 91.96% | 92.02% | 81.29% | 75.68% | 65.20% |
| EPS Basic | 98.57% | 97.87% | 90.70% | 85.02% | 77.32% |
| Normalized Basic EPS | 99.73% | 98.61% | 94.00% | 87.68% | 78.89% |
| EPS Diluted | 98.57% | 97.87% | 90.70% | 85.02% | 77.32% |
| Normalized Diluted EPS | 99.73% | 98.61% | 94.00% | 87.68% | 78.89% |
| Average Basic Shares Outstanding | 796.35% | 744.99% | 585.34% | 247.09% | 144.08% |
| Average Diluted Shares Outstanding | 796.35% | 744.99% | 585.34% | 247.09% | 144.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |